Wall Street Zen upgraded shares of Hemab Therapeutics (NASDAQ:COAG – Free Report) to a hold rating in a research note published on Saturday morning.
Hemab Therapeutics Stock Performance
Shares of COAG stock opened at $25.12 on Friday. Hemab Therapeutics has a 52 week low of $23.48 and a 52 week high of $36.61.
Insider Activity at Hemab Therapeutics
In related news, Director Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock in a transaction dated Wednesday, May 6th. The stock was bought at an average price of $24.60 per share, with a total value of $1,673,242.80. Following the transaction, the director directly owned 6,314,525 shares in the company, valued at $155,337,315. This represents a 1.09% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 2,840,429 shares of company stock worth $52,222,476.
Featured Stories
- Five stocks we like better than Hemab Therapeutics
- Buffett Spent 60 Years Ignoring Tech and the Bill Is Coming Due
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
Receive News & Ratings for Hemab Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemab Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
